根据最新临床试验的初步研究结果,美国食品和药品管理局(FDA)于2012年6月29日发布药物安全警告:单剂量静脉注射昂丹司琼32 mg可引起患者QT间期延长,甚至出现致死性心律失常——尖端扭转型室性心动过速[1]。 According to preliminary findings from the latest clinical trial, the U.S. Food and Drug Administration (FDA) issued a drug safety warning on June 29, 2012: A single intravenous infusion of 32 mg of ondansetron led to prolonged or even prolonged QT intervals Fatal arrhythmia - torsades de pointes ventricular tachycardia [1].